Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children

Claudia Fortuny, Dan Duiculescu, Katharine Cheng, Harmony P Garges, Mark Cotton, Desamparados Pérez Tamarirt, Susan L Ford, Mary Beth Wire, Naomi Givens, Lisa L Ross, Yu Lou, Teodora Perger, Jörg Sievers, Claudia Fortuny, Dan Duiculescu, Katharine Cheng, Harmony P Garges, Mark Cotton, Desamparados Pérez Tamarirt, Susan L Ford, Mary Beth Wire, Naomi Givens, Lisa L Ross, Yu Lou, Teodora Perger, Jörg Sievers

Abstract

Background: Pharmacokinetics, safety and antiviral activity of twice-daily fosamprenavir with or without ritonavir were evaluated in 2- to 18-year-old protease inhibitor-naïve and -experienced HIV-1-infected children.

Methods: Serial pharmacokinetic samples were collected at week 2 and predose samples every 4-12 weeks. Safety and plasma HIV-1 RNA were monitored every 4-12 weeks.

Results: Twenty protease inhibitor-naïve 2- to <6-year-old subjects received antiretroviral treatment including unboosted fosamprenavir twice-daily, whereas 89 protease inhibitor-naïve and -experienced 2- to 18-year-old subjects received fosamprenavir/ritonavir-containing therapy twice-daily. Median fosamprenavir exposure was 891 days (range 15-1805 days), with 88% exposed >48 weeks. Twice-daily doses of fosamprenavir/ritonavir 23/3 mg/kg in 2- to <6-year olds, 18/3 mg/kg in ≥6-year olds and 700/100 mg in adolescents achieved plasma amprenavir exposures comparable with or higher than 700/100 mg twice-daily in adults while fosamprenavir 30 mg/kg twice-daily in 2- to <6-year olds led to exposures higher than 1400 mg twice-daily in adults. The proportion of subjects with HIV-1 RNA <400 copies/mL at week 48 was 60% for fosamprenavir and 53-74% for fosamprenavir/ritonavir (intent-to-treat [exposed], snapshot analysis). Median increases in absolute and relative (percentage) CD4 counts from baseline to week 48 occurred in both the fosamprenavir (340 cells/mm; 8%) and fosamprenavir/ritonavir group (190 cells/mm; 8%). The most common adverse events were vomiting, cough, and diarrhea; 18 subjects experienced serious adverse events, including 9 with suspected abacavir hypersensitivity.

Conclusions: Fosamprenavir regimens administered to HIV-1-infected children aged 2-18 years were generally well-tolerated and provided sustained antiviral activity over 48 weeks, with plasma amprenavir exposures comparable with or higher than adults.

Conflict of interest statement

M.C. received support from a grant from ViiV Healthcare and payment for lectures, including service on speakers’ bureaus, from Abbott Laboratories. K.C., H.P.G., S.L.F., M.B.W., N.G., L.L.R., Y.L., T.P. and J.S. are employees of GlaxoSmithKline. The authors have no other funding or conflicts of interest to disclose

References

    1. Gortmaker SL, Hughes M, Cervia J, et al. Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–1528.
    1. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283:492–498.
    1. Violari A, Cotton MF, Gibb DM, et al. CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–2244.
    1. AIDSinfo: Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 16, 2010. Available at: . Accessed September 3, 2012.
    1. PENTA: 2009 Guidelines for the use of Antiretroviral therapy. HIV Med. 2009;10:591–613.
    1. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT Study: A 48-week open-label study to compare the antiviral efficacy and safety of GW43908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. JAIDS. 2004;35:22–32.
    1. Gathe JC, Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529–1537.
    1. DeJesus E, Lamarca A, Sension M, et al. The Context Study: Efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results).. In: 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA; February 10–14, 2003; Abstract 178.
    1. Church J, Rathore M, Rubio T, et al. A Phase III study of amprenavir (APV, Agenerase) in protease inhibitor naïve and expereinced HIV infected children and adolescents.. In: 7th Conference on Retrovirus and Opportunistic Infections (CROI), San Francisco, CA; January 30 to February 2, 2000; Abstract 693.
    1. Blanche S, Fetter A, Cox H, et al. A Phase II study of amprenavir (APV, 141W94, Agenerase) in antiretroviral-experienced children with HIV-infection.. In: 7th Conference on Retrovirus and Opportunistic Infections (CROI), San Francisco, CA; January 30 to February 2, 2000; Abstract 695.
    1. Stein DS, Lou Y, Johnson M, et al. Prob2004 Study Team. Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children. J Clin Pharmacol. 2004;44:1301–1308.
    1. Chadwick EG, Borkowsky W, Fortuny Guasch C, et al. Antiviral activity of fosamprenavir/ritonavir (FPV/RTV) QD regimens in HIV-infected pediatric subjects ages 2 to 18 years (48 week interim data, Study APV20003).. In: 14th Conference on Retroviruses and Opportunistic Infections (CROI), Los Angeles, CA; February 25–28, 2007; Abstract 719.
    1. Lexiva. US Prescribing Information. 2012
    1. Fisher J, Gastonguay MR, Knebel W, et al. In: The American Conference on Pharmacometrics (ACoP) Tucson, AZ: March 9–12, 2008. Population pharmacokinetic modeling of fosamprenavir in pediatric HIV-infected patients. Available at: Accessed August 1, 2013.
    1. Division of AIDS. Table for grading the severity of adult and pediatric adverse events, December, 2004. Available at: . Accessed August 23, 2012.
    1. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18:156–163.
    1. Ross L, Cotton M, Cassim H, et al. HIV-1 drug resistance and mutational profile in fosamprenavir-treated HIV-infected children aged 2 months to 18 years at start of therapy.. In: 19th International AIDS Conference (IAC), Washington, DC; July 22–27, 2012; Abstract MOPE040.
    1. Torres HA, Arduino RC. Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther. 2007;5:349–363.
    1. Eron J, Jr, Yeni P, Gathe J, Jr, et al. KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476–482.
    1. Palladino C, Briz V, Policarpo SN, et al. Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 2010;29:563–566.
    1. Judd A, Ene L, Goetghebuer T, et al. Use and safety of fosamprenavir in HIV-infected children in the European Union: an ongoing postmarketing surveillance study.. In: 6th International AIDS Society Conference (IAS), Rome; July 12–17, 2011; Abstract CDB416.
    1. Kenny J, Musiime V, Judd A, et al. Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. Curr Opin HIV AIDS. 2012;7:305–316.
    1. Sáez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216–224.
    1. Reyataz. Summary of Product Characteristics. 2012
    1. Blanche S, Bologna R, Cahn P, et al. 48-week safety and efficacy of darunavir/ritonavir (DRV/R) in treatment-experienced children and adolescents in DELPHI.. In: 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008), Washington, DC; October 25–28, 2008; Washington, DC: American Society for Microbiology; 2008. Abstract H-894.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit